# Efficacy and Safety in a Randomised Acute Pain Study of MR308 (Tramadol/Celecoxib).

> **NCT02982161** · PHASE3 · COMPLETED · sponsor: **Mundipharma Research GmbH & Co KG** · enrollment: 818 (actual)

## Conditions studied

- Acute Pain

## Interventions

- **DRUG:** MR308
- **DRUG:** Tramadol
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02982161
- **Lead sponsor:** Mundipharma Research GmbH & Co KG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-28
- **Primary completion:** 2018-01-04
- **Final completion:** 2018-01-04
- **Target enrollment:** 818 (ACTUAL)
- **Last updated:** 2018-05-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02982161

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02982161, "Efficacy and Safety in a Randomised Acute Pain Study of MR308 (Tramadol/Celecoxib).". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02982161. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*